• Publications
  • Influence
Plasma AR and abiraterone-resistant prostate cancer
TLDR
Tumor DNA samples from the blood of 97 patients with castration-resistant prostate cancer were analyzed and found that androgen receptor amplifications were present from the beginning and correlated with abiraterone resistance, suggesting that detection of these amplifications should be useful for identifying abiraton-resistant cancers before starting treatment. Expand
Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis.
TLDR
It is demonstrated that PDGF-BB and FGF2 reciprocally increase their EC and mural cell responses, leading to disorganized neovascularization and metastasis, suggesting that intervention of this non-VEGF reciprocal interaction loop for the tumor vasculature could be an important therapeutic target for the treatment of cancer and metastases. Expand
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
TLDR
The authors demonstrate that endometrial cancer cell lines that lack the tumor suppressor protein PTEN show defects in the repair of DNA damage and are consequently very sensitive to drugs that block poly(ADP) ribose polymerase (PARP), an enzyme critical for DNA repair. Expand
Functional viability profiles of breast cancer.
TLDR
A functional genetic screen in >30 commonly used models of breast cancer to identify genes critical to the growth of specific breast cancer subtypes is carried out and potential new therapeutic targets for PTEN-mutated cancers and for estrogen receptor-positive breast cancers are described. Expand
Emerging therapeutic targets in endometrial cancer
TLDR
The identification of activating mutations of kinases (for example PIK3CA and FGFR2) and loss of function of genes related to DNA repair ( for example PTEN) may lead to more biology-driven clinical trials exploiting the concepts of oncogene addiction and synthetic lethality. Expand
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
TLDR
Evidence is discussed that the clinical use of PARP inhibition may be broader than targeting of cancers in BRCA1/2 germ-line mutation carriers, and suggests a potentially broader scope for PARP inhibitors. Expand
Functional characterization of the 19q12 amplicon in grade III breast cancers
TLDR
The 19q12 amplicon may harbour more than a single 'driver', given that expression of POP4, PLEKHF1, CCNE1 and TSZH3 is required for the survival of cancer cells displaying their amplification. Expand
Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple‐negative and basal‐like breast cancers
TLDR
Breast AdCCs constitute an entity distinct from grade‐matched and triple‐ negative and basal‐like IDC‐NSTs, emphasizing the importance of histological subtyping of triple‐negative and basal-like breast carcinomas. Expand
Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers
TLDR
Results indicate that specific amplified and/ or overexpressed genes found in ERBB2-amplified breast cancer may mediate response to ER BB2-targeting agents. Expand
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
TLDR
Plasma AR status assessment using ddPCR identifies CRPC with worse outcome to enzalutamide or abiraterone and Prospective evaluation of treatment decisions based on plasma AR is now required. Expand
...
1
2
3
4
5
...